CP 471474 inhibits MMPs, enzymes that degrade extracellular matrix components, thus having potential therapeutic applications in cancer and chronic inflammatory diseases. It targets MMP-1, MMP-13, MMP-2, MMP-3, and MMP-9.
CP 471474 is studied to evaluate its potential in treating diseases involving excessive degradation of extracellular matrix proteins, like cancer and fibrosis.
CD BioGlyco is a world-class biotechnology company with offices in many countries. Our products and services provide a viable option to what is otherwise available.
